On October 7th, AstraZeneca and CSPC Group Co., Ltd. have entered into an exclusive licensing agreement to advance the development of a preclinical innovative small molecule lipoprotein(a) (Lp(a)) inhibitor. This compound has the potential to bring more benefits to patients with dyslipidemia and further strengthens our cardiovascular product pipeline, helping us address the main risk factors leading to chronic cardiovascular diseases.
Under the agreement, AstraZeneca will obtain the preclinical candidate small molecule drug YS2302018 from CSPC Group, an oral lipoprotein(a) inhibitor, for the development of new lipid-lowering therapies, as well as for monotherapy or combination therapy for various cardiovascular diseases, including co-administration with the oral small molecule PCSK9 inhibitor AZD0780.
According to the terms of the agreement, CSPC Group will receive an upfront payment of $100 million. In addition, CSPC Group will also be eligible for up to $1.92 billion in development and commercialization milestone payments, as well as tiered royalty payments.
AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy
If you are looking for similar products, please feel free to contact DrugTimes BD Team. We can help you find quality products and partners quickly.
Please contact us at BD@drugtimes.cn.
Thank you very much!
发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权